RRM1 and neoplasm: Among drug targets identified, RRM1 and GSR are both involved in glutathione metabolism and are targets of drugs used to treat various neoplasms; glutamate ionotropic receptor NMDA type subunit 2B (GRIN2B) is involved in long-term neuronal potentiation; and guanylate cyclase 2C (GUCY2C) modulates gut cyclic GMP signaling.